Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06628310
Title A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA)
Acronym AndroMETa-GEA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR

Facility Status City State Zip Country Details
City of Hope National Medical Center /ID# 268690 RECRUITING Duarte California 91010 United States Details
City of Hope Orange County Lennar Foundation Cancer Center /ID# 272630 RECRUITING Irvine California 92618 United States Details
Hattiesburg Clinic /ID# 268572 RECRUITING Hattiesburg Mississippi 39401 United States Details
Millennium Research & Clinical Development /ID# 268540 RECRUITING Houston Texas 77090 United States Details
Tel Aviv Sourasky Medical Center /ID# 267755 RECRUITING Tel Aviv Tel-Aviv 6423906 Israel Details
Hadassah Medical Center-Hebrew University /ID# 267753 RECRUITING Jerusalem 91120 Israel Details
National Cancer Center Hospital /ID# 268648 RECRUITING Chuo-Ku Tokyo 104-0045 Japan Details
China Medical University Hospital /ID# 267667 RECRUITING Taichung 404 Taiwan Details
Taipei Veterans General Hospital /ID# 267664 RECRUITING Taipei City 112 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field